These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29966685)

  • 1. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
    Mühlebach S
    Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicines: The magic bullets reaching their target?
    Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
    Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tackling the challenges of nanomedicines: are we ready?
    Hertig JB; Shah VP; Flühmann B; Mühlebach S; Stemer G; Surugue J; Moss R; Di Francesco T
    Am J Health Syst Pharm; 2021 Jun; 78(12):1047-1056. PubMed ID: 33599767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
    Hussaarts L; Mühlebach S; Shah VP; McNeil S; Borchard G; Flühmann B; Weinstein V; Neervannan S; Griffiths E; Jiang W; Wolff-Holz E; Crommelin DJA; de Vlieger JSB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):39-49. PubMed ID: 28445611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflections on FDA Draft Guidance for Products Containing Nanomaterials: Is the Abbreviated New Drug Application (ANDA) a Suitable Pathway for Nanomedicines?
    Emily M; Ioanna N; Scott B; Beat F
    AAPS J; 2018 Aug; 20(5):92. PubMed ID: 30128758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory Science Approach in Pharmaceutical Development of Follow-on Versions of Non-Biological Complex Drug Products.
    Zagalo DM; Simões S; Sousa J
    J Pharm Sci; 2022 Oct; 111(10):2687-2713. PubMed ID: 35901943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to select a nanosimilar.
    Astier A; Barton Pai A; Bissig M; Crommelin DJA; Flühmann B; Hecq JD; Knoeff J; Lipp HP; Morell-Baladrón A; Mühlebach S
    Ann N Y Acad Sci; 2017 Nov; 1407(1):50-62. PubMed ID: 28715605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractal geometry as a new approach for proving nanosimilarity: a reflection note.
    Demetzos C; Pippa N
    Int J Pharm; 2015 Apr; 483(1-2):1-5. PubMed ID: 25659328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The similarity question for biologicals and non-biological complex drugs.
    Crommelin DJ; Shah VP; Klebovich I; McNeil SE; Weinstein V; Flühmann B; Mühlebach S; de Vlieger JS
    Eur J Pharm Sci; 2015 Aug; 76():10-7. PubMed ID: 25912826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines in clinical practice: Are colloidal iron sucrose ready-to-use intravenous solutions interchangeable?
    Di Francesco T; Sublet E; Borchard G
    Eur J Pharm Sci; 2019 Apr; 131():69-74. PubMed ID: 30742979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
    Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
    Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Do Hospital Pharmacists Approach Substitution of Nanomedicines? Insights from a Qualitative Pilot Study and a Quantitative Market Research Analysis in Five European Countries.
    Sofia N; Mühlebach S; Musazzi UM; Khatib R; Martinez Sesmero JM; Lipp HP; Surugue J; Di Francesco T; Flühmann B
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Therapeutic Equivalence for the Follow-On Version of Intravenously Administered Non-Biological Complex Drugs.
    Sun Z; Jiang J; Chen X
    Clin Pharmacokinet; 2020 Aug; 59(8):995-1004. PubMed ID: 32328977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
    Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
    Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
    Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
    Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines in the EU-Regulatory Overview.
    Pita R; Ehmann F; Papaluca M
    AAPS J; 2016 Nov; 18(6):1576-1582. PubMed ID: 27527889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.
    Lunawat S; Bhat K
    Ther Innov Regul Sci; 2020 Sep; 54(5):991-1000. PubMed ID: 31960290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.